tiprankstipranks
Trending News
More News >
Consun Pharmaceutical Group Ltd. (HK:1681)
:1681
Advertisement

Consun Pharmaceutical Group Ltd. (1681) AI Stock Analysis

Compare
6 Followers

Top Page

HK:1681

Consun Pharmaceutical Group Ltd.

(Frankfurt:1681)

Rating:79Outperform
Price Target:
HK$14.00
▲(8.70%Upside)
Consun Pharmaceutical Group Ltd. receives a high overall score driven by strong financial performance and attractive valuation, with an emphasis on robust revenue growth, profitability, and a compelling P/E ratio combined with a high dividend yield. While bullish technical indicators are present, caution is advised due to overbought signals. Lack of recent cash flow data and earnings call analysis slightly limits the assessment.
Positive Factors
New Product Development
Potential introduction of new drugs, with focus areas being identified, could be a catalyst and drive sales growth ahead.
Risk Reduction
Recent exclusion in the national tender of finished Chinese medicines indicates lower risk on price cut for its key product uremic clearance granule (UCG) in the next 2 years.
Negative Factors
Economic Impact
Sales volume growth slowdown due to a slowing economy.

Consun Pharmaceutical Group Ltd. (1681) vs. iShares MSCI Hong Kong ETF (EWH)

Consun Pharmaceutical Group Ltd. Business Overview & Revenue Model

Company DescriptionConsun Pharmaceutical Group Ltd. (1681) is a China-based pharmaceutical company engaged in the research, development, manufacturing, and marketing of modern Chinese medicines and medical contrast medium products. The company primarily focuses on nephrology, orthopedics, and dermatology sectors, providing a diverse range of therapeutic solutions aimed at addressing specific medical needs. Consun Pharmaceutical is recognized for its innovation in traditional Chinese medicine formulations, integrating modern scientific approaches to enhance efficacy and safety.
How the Company Makes MoneyConsun Pharmaceutical Group Ltd. generates revenue through the sale of its pharmaceutical products, primarily focusing on modern Chinese medicines and medical contrast medium products. The company's key revenue streams include the domestic market in China, where it distributes its products through a network of distributors and direct sales to hospitals and pharmacies. Consun leverages its research and development capabilities to enhance its product offerings and maintain a competitive edge in the market. The company may also engage in strategic partnerships, licensing agreements, and collaborations to expand its product reach and enhance its market position, although specific details on partnerships are not provided.

Consun Pharmaceutical Group Ltd. Financial Statement Overview

Summary
Consun Pharmaceutical Group Ltd. demonstrates strong revenue growth and profitability margins, with a robust balance sheet and improved equity position. However, cash flow analysis is limited due to missing recent data, and high cash reserves suggest potential underutilization of funds.
Income Statement
85
Very Positive
Consun Pharmaceutical Group Ltd. has demonstrated strong growth in revenue, consistently increasing from 2019 to 2024. The company shows impressive profitability with a gross profit margin consistently above 75% and a net profit margin improving from 4.6% in 2019 to 30.7% in 2024. EBIT and EBITDA margins have also shown positive trends, indicating effective cost management. However, the high growth rate may pose sustainability challenges in future periods.
Balance Sheet
78
Positive
The company maintains a robust balance sheet with a strong equity position and increasing total assets. The debt-to-equity ratio has improved, reflecting reduced leverage over the years. The return on equity has also improved significantly, indicating efficient use of equity capital. Nonetheless, high cash reserves might suggest underutilization of funds, which could be optimized for growth or shareholder returns.
Cash Flow
72
Positive
Consun Pharmaceutical Group Ltd. has maintained positive free cash flow consistently, although recent data is unavailable for comprehensive analysis. The company has shown the ability to generate cash from operations, but the lack of recent cash flow data limits a full assessment. Historical trends suggest sound cash flow management, but recent growth in free cash flow percentages are needed for a clearer picture.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.97B2.59B2.34B2.04B1.75B
Gross Profit2.24B1.92B1.76B1.53B1.32B
EBITDA1.05B963.06M785.89M728.71M618.79M
Net Income910.46M784.53M682.91M590.17M498.79M
Balance Sheet
Total Assets5.85B5.51B4.89B4.36B3.95B
Cash, Cash Equivalents and Short-Term Investments3.87B3.58B3.04B2.43B1.94B
Total Debt267.17M511.53M460.18M610.97M549.41M
Total Liabilities1.46B1.59B1.45B1.45B1.43B
Stockholders Equity4.10B3.63B3.15B2.62B2.22B
Cash Flow
Free Cash Flow977.99M766.41M896.09M627.29M818.36M
Operating Cash Flow1.09B818.97M947.68M725.54M867.06M
Investing Cash Flow-186.91M-231.77M-368.80M-298.31M-25.70M
Financing Cash Flow-729.26M-280.10M-342.20M-166.66M-279.80M

Consun Pharmaceutical Group Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price12.88
Price Trends
50DMA
11.11
Positive
100DMA
9.93
Positive
200DMA
8.87
Positive
Market Momentum
MACD
0.48
Negative
RSI
86.02
Negative
STOCH
95.86
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1681, the sentiment is Positive. The current price of 12.88 is above the 20-day moving average (MA) of 11.76, above the 50-day MA of 11.11, and above the 200-day MA of 8.87, indicating a bullish trend. The MACD of 0.48 indicates Negative momentum. The RSI at 86.02 is Negative, neither overbought nor oversold. The STOCH value of 95.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1681.

Consun Pharmaceutical Group Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
€10.71B10.7023.28%4.66%12.70%9.91%
74
Outperform
HK$6.35B6.9711.61%0.83%-18.09%-15.08%
70
Outperform
HK$11.19B12.298.89%0.58%4.91%-11.80%
65
Neutral
HK$14.96B26.935.88%-42.02%-76.29%
60
Neutral
HK$17.07B5.63-7.44%2.87%11.55%-28.15%
58
Neutral
$11.83B200.000.25%0.44%-10.72%-95.88%
49
Neutral
HK$12.41B-4.93%1.58%-0.11%-290.77%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1681
Consun Pharmaceutical Group Ltd.
12.88
7.64
145.85%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
8.40
3.46
70.04%
HK:2877
China Shineway Pharmaceutical Group Limited
8.40
0.82
10.82%
HK:1558
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
16.00
6.83
74.48%
HK:0570
China Traditional Chinese Medicine Holdings Co
2.32
-0.90
-27.97%
HK:0460
Sihuan Pharmaceutical Holdings Group
1.33
0.82
160.78%

Consun Pharmaceutical Group Ltd. Corporate Events

Consun Pharmaceutical Group Announces Board Composition and Committee Roles
Jun 20, 2025

Consun Pharmaceutical Group Ltd. has announced the composition of its Board of Directors and the roles within its four established committees. This organizational update may influence the company’s governance and strategic direction, potentially impacting stakeholders and the company’s positioning in the pharmaceutical industry.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Group Ltd. Forms Nomination Committee to Strengthen Governance
Jun 20, 2025

Consun Pharmaceutical Group Ltd. has announced the establishment of a Nomination Committee within its Board of Directors, effective from June 2025. This committee, primarily composed of independent non-executive directors, will oversee the nomination process for board members, ensuring diversity and independence in its composition. The move is aimed at enhancing corporate governance and ensuring a robust selection process for board appointments.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Group Updates Nomination Committee for Enhanced Governance
Jun 20, 2025

Consun Pharmaceutical Group Ltd. announced changes in its Nomination Committee, effective June 20, 2025, with Mr. An Meng stepping down and Dr. Zhang Lihua joining as a member. This change aligns with the updated Corporate Governance Code and aims to enhance the company’s governance practices, thereby potentially improving its overall performance and diversity.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Launches HKD200 Million Share Repurchase Program
Jun 13, 2025

Consun Pharmaceutical Group Ltd. has announced a share repurchase program, utilizing a general mandate granted by shareholders. The program aims to repurchase up to HKD200 million worth of shares from the open market, reflecting the company’s confidence in its business prospects and belief that its current share price undervalues its intrinsic worth. This initiative is aligned with the company’s long-term strategy to optimize capital structure and enhance shareholder value, while maintaining sufficient financial resources for ongoing operations.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical Successfully Passes AGM Resolutions
May 22, 2025

Consun Pharmaceutical Group Ltd. announced the successful passage of all proposed resolutions at its Annual General Meeting held on May 22, 2025. Key resolutions included the approval of the financial statements for 2024, re-election of several directors, declaration of a final dividend, and re-appointment of KPMG as auditors. The results reflect strong shareholder support and are likely to positively impact the company’s governance and financial strategies.

The most recent analyst rating on (HK:1681) stock is a Buy with a HK$7.80 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.

Consun Pharmaceutical’s Traditional Chinese Medicine Product Gains Protected Status
Apr 30, 2025

Consun Pharmaceutical Group Ltd. announced that its product, Kidney Repair and Edema Alleviation Granules, has been approved as a Class 2 Protected Product of Traditional Chinese Medicine by the National Medical Products Administration. This approval grants the product a state protection period of seven years, during which other enterprises are prohibited from imitating it. The recognition is expected to support the company’s long-term development and strengthen its market position.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025